SelectiveLXRinverseagonist.Exhibitsnosignificantactivityatothernuclearreceptorsatmaximallyeffectiveconcentration.InhibitstheWarburgeffectandlipogenesisbydown-regulationofLXR-mediatedgeneexpression.SelectivelyreducescellviABIlityandinducesapoptosisincancercelllinesinvitro.Suppresseshepaticsteatosisandinhibitsgrowthoftumorxenograftsinmice.
M.Wt | 626.62 |
Formula | C31H32BrNO4S2 |
Storage | Storeat+4°C |
Purity | ≥98%(HPLC) |
CASNumber | 1613028-81-1 |
PubChemID | 76073169 |
InChIKey | FYQFEJFTCLKXTQ-UHFFFAOYSA-N |
Smiles | CC1=CC(C)=CC(C)=C1S(N(CCC2=CC=CC(Br)=C2)CC(C=C3)=CC=C3C4=CC(S(=O)(C)=O)=CC=C4)(=O)=O |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Solvent | MaxConc.mg/mL | MaxConc.mM | |
---|---|---|---|
Solubility | |||
DMSO | 12.53 | 20 |
Thefollowingdataisbasedontheproductmolecularweight626.62.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
---|---|---|---|
1mM | 1.6mL | 7.98mL | 15.96mL |
5mM | 0.32mL | 1.6mL | 3.19mL |
10mM | 0.16mL | 0.8mL | 1.6mL |
50mM | 0.03mL | 0.16mL | 0.32mL |